Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01971645 · ClinicalTrials.gov registry record · Phase 3
Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy
A Phase 3 study, sponsored by Nationwide Children's Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
NCT01971645 is a Phase 3 study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 77 participants.
The verdict
NCT01971645, a Phase 3 study, has completed, sponsored by Nationwide Children's Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
Study Summary
If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2 mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.
Interventions
- DRUG Dexamethasone
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01971645
The ClinicalTrials.gov registry entry for NCT01971645 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT01971645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01971645 about?
NCT01971645 is a clinical study titled "Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy". If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2 mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.
What is the current status of trial NCT01971645?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2014-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01971645?
The interventions under investigation include: Dexamethasone (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT01971645?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.